Director Frank Steven converts 71,839 RSUs into Precigen (PGEN) common stock

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PRECIGEN, INC. director Frank Steven reported the vesting and exercise of restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units converted into 71,839 shares of Precigen common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.

The footnotes state that each RSU represented a contingent right to receive one share of common stock and that the RSUs vested in full on March 13, 2026. After the transaction, Steven directly held 1,226,391 shares of Precigen common stock, with no remaining RSU position shown in this filing.

Insider Trade Summary

71,839 shares exercised/converted

Mixed 2 txns

Insider Frank Steven

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	71,839	$0.00	--
Exercise	Common Stock	71,839	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 1,226,391 shares (Direct)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. The RSUs vested in full on March 13, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/16/2026 - 05:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frank Steven

(Last)

(First)

(Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN

20876

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/13/2026		M		71,839	A	⁽¹⁾	1,226,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/13/2026		M			71,839	⁽²⁾	⁽²⁾	Common Stock	71,839	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vested in full on March 13, 2026.

	/s/ Steven Frank, by Donald P. Lehr, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Precigen (PGEN) director Frank Steven report?

Director Frank Steven reported the vesting and exercise of restricted stock units into common stock. On March 13, 2026, 71,839 RSUs converted into 71,839 shares of Precigen common stock as part of his equity compensation, not an open-market trade.

How many Precigen (PGEN) shares did Frank Steven acquire in this Form 4?

Frank Steven acquired 71,839 shares of Precigen common stock through the exercise of restricted stock units. Each RSU represented a contingent right to receive one share, and they vested in full on March 13, 2026, triggering the share issuance at a stated price of $0.00.

What is Frank Steven’s Precigen (PGEN) shareholding after this Form 4?

After the reported RSU exercise, Frank Steven directly holds 1,226,391 shares of Precigen common stock. This total reflects his position following the conversion of 71,839 restricted stock units on March 13, 2026, as disclosed in the Form 4 transaction details.

Were the Precigen (PGEN) shares in this Form 4 bought or part of compensation?

The shares were part of equity compensation, not an open-market purchase. The filing shows 71,839 restricted stock units that vested and converted into the same number of common shares at a stated price of $0.00, consistent with a stock-based award vesting event.

Did Frank Steven sell any Precigen (PGEN) shares in this Form 4 filing?

The Form 4 does not show any sales by Frank Steven. It reports only an acquisition via derivative exercise, where 71,839 restricted stock units vested and converted into 71,839 shares of common stock, increasing his direct holdings to 1,226,391 shares.

What do the footnotes in Frank Steven’s Precigen (PGEN) Form 4 explain?

The footnotes explain that each restricted stock unit represented a contingent right to receive one share of Precigen common stock. They also clarify that the RSUs vested in full on March 13, 2026, which is when the conversion into common shares occurred.